Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 20/20 | 0.44 |
| ▸ | CASP8 | Q14790 | 11/20 | 0.43 |
| ▸ | CASP6 | P55212 | 6/20 | 0.43 |
| ▸ | CASP7 | P55210 | 5/20 | 0.43 |
| ▸ | CASP9 | P55211 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7201731 | 0.92 | CASP3 (0.43) | CASP3CASP8CASP6CASP7CASP1 | |
| SCHEMBL5667954 | 0.89 | CASP3 (0.47) | CASP3CASP8CASP6CASP7CASP9 | |
| SCHEMBL29382429 | 0.89 | CASP3 (0.47) | CASP3CASP8CASP6CASP7CASP9 | |
| SCHEMBL5668068 | 0.89 | CASP3 (0.47) | CASP3CASP8CASP6CASP7CASP9 | |
| SCHEMBL26371958 | 0.89 | CASP3 (0.47) | CASP3CASP8CASP6CASP7CASP9 | |
| SCHEMBL5667112 | 0.87 | CASP3 (0.47) | CASP3CASP8CASP6CASP7CASP9 | |
| SCHEMBL27583485 | 0.86 | CASP3 (0.53) | CASP3CASP8CASP6CASP7 | |
| SCHEMBL7201348 | 0.86 | CASP3 (0.53) | CASP3CASP8CASP6CASP7 | |
| SCHEMBL7204052 | 0.86 | CASP3 (0.52) | CASP3CASP8CASP6 | |
| SCHEMBL7200864 | 0.85 | CASP3 (0.60) | CASP3CASP8CASP6CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1647279-A2 | Inhibition of apoptosis using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors | Idun Pharmaceuticals, Inc. (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6693096-B2 | SUPPRESSING PROTEASE ACTIVITY | IDUN PHARMACEUTICALS, INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030186842-A1 | Contacting a cell population with an inhibiting effective amount of a reagent that suppresses the protease activity of at least one member of the interleukin-1beta- converting enzyme (ICE)/CED-3 family | IDUN PHARMACEUTICALS, INC. (US) | 2003-10-02 | — | — | US | disclosed |
| US-6610683-B2 | Programmed cell death; expansion of hematopoietic cells, for prolonging viability of an organ for transplantation, and maintaining viability of cell lines used in bioproduction | IDUN PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030119748-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2003-06-26 | — | — | US | disclosed |
| US-6531467-B2 | Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors | IDUN PHARMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| US-6528506-B2 | Viability of organs transplants | IDUN PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20030039661-A1 | Methods, compositions and kits for preserving antigenicity | IDUN PHARMACEUTICALS, INC. | 2003-02-27 | — | — | US | disclosed |
| EP-0920444-B1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS INC (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6489353-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; CENTRAL NERVOUS SYSTEM DISORDERS | IDUN PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020147171-A1 | Inhibition of apoptosis using interleukin-1beta converting enzyme (ICE)/CED-3 family inhibitors | IDUN PHARMACEUTICALS, INC. (US) | 2002-10-10 | — | — | US | disclosed |
| US-20020128306-A1 | Programmed cell death; expansion of hematopoietic cells, for prolonging viability of an organ for transplantation, and maintaining viability of cell lines used in bioproduction | IDUN PHARMACEUTICALS, INC. | 2002-09-12 | — | — | US | disclosed |
| US-20020123522-A1 | Inhibition of inflammation using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors | IDUN PHARMACEUTICALS, INC. (US) | 2002-09-05 | — | — | US | disclosed |
| US-20020025935-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| EP-1159291-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYLCARBONYLDIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| US-20010044415-A1 | Inhibition of apoptosis using interleukin-1B-converting enzyme (ICE)/CED-3 family inhibitors | FRITZ LAWRENCE C (US) | 2001-11-22 | — | — | US | disclosed |
| US-6200969-B1 | CONTACTING CELLS WITH REAGENT WHICH SUPPRESSES PROTEASE ACTIVITY OF INTERLEUKIN-1.BETA.-CONVERTING ENZYME (ICE)/CED-3 FAMILY, INHIBITING APOPTOSIS IN CELL POPULATION TO EXPANDING OR INCREASING SURVIVAL OF CELL POPULATION | IDUN PHARMACEUTICALS, INC. | 2001-03-13 | — | — | US | disclosed |
| US-6184244-B1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2001-02-06 | — | — | US | disclosed |
| WO-2001000658-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYLCARBONYLDIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| US-5877197-A | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 1999-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186842-A1 | Contacting a cell population with an inhibiting effective amount of a reagent that suppresses the protease activity of at least one member of the interleukin-1beta- converting enzyme (ICE)/CED-3 family | CASP1, SERPINB1, IL1B | CASP3 5/4885CASP8 82/4885CASP6 31/4885 |
| US-20030039661-A1 | Methods, compositions and kits for preserving antigenicity | CASP1, CASP3, APAF1 | CASP3 2/4885CASP8 7/4885CASP6 15/4885 |
| US-20020025935-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CASP3, CASP1, IAPP | CASP3 1/4885CASP8 60/4885CASP6 37/4885 |
| US-20020123522-A1 | Inhibition of inflammation using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors | IL1B, CASP1, IL1A | CASP3 22/4885CASP8 103/4885CASP6 53/4885 |
| US-20030119748-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | CASP3, CASP1, IAPP | CASP3 1/4885CASP8 60/4885CASP6 37/4885 |
| US-20020147171-A1 | Inhibition of apoptosis using interleukin-1beta converting enzyme (ICE)/CED-3 family inhibitors | CASP1, CASP3, APAF1 | CASP3 2/4885CASP8 23/4885CASP6 6/4885 |
| US-20010044415-A1 | Inhibition of apoptosis using interleukin-1B-converting enzyme (ICE)/CED-3 family inhibitors | CASP1, IL1B, APAF1 | CASP3 4/4885CASP8 40/4885CASP6 6/4885 |
| US-20020128306-A1 | Programmed cell death; expansion of hematopoietic cells, for prolonging viability of an organ for transplantation, and maintaining viability of cell lines used in bioproduction | CASP1, CASP3, MCL1 | CASP3 2/4885CASP8 14/4885CASP6 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.